Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Transcode Therapeutics Inc(RNAZ)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RNAZ
09/24/2026: RNAZ (1-star) is currently NOT-A-BUY. Pass it for now.
Transcode Therapeutics is a small-cap clinical-stage biotechnology company focused on developing RNA-targeted therapeutics for metastatic cancer using its proprietary TTX delivery platform. The company's main strength lies in this specialized delivery technology, which aims to solve core hurdles in RNA-based drug administration. While the company holds a unique scientific niche, it remains pre-revenue and faces the extreme execution and financial risks typical of early-stage biotech. The primary investment story rests on the potential success of its lead candidate, TTX-MC138. Investors should monitor clinical trial results, capital dilution risks, and potential partnership developments, as these are the main drivers of its volatile future valuation.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The high-risk nature of clinical-stage biotech offers high potential growth but with extreme uncertainty. |
| Momentum investor | Weak fit | Momentum is generally negative, and the stock lacks the trading volume/catalysts often sought by this style. |
| Value investor | Weak fit | The company lacks revenue and positive earnings, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | There is no dividend income or realistic prospect for dividends in the near future. |
| Low-risk investor | Weak fit | This is a speculative small-cap biotech with high volatility and extreme risk of total capital loss. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As a clinical-stage micro-cap, the stock price can experience extreme swings based on minor news or sector sentiment. |
| Valuation risk | High | Without revenue, valuation is highly subjective and vulnerable to market corrections. |
| Competition risk (RNA therapeutics) | Medium / high | Large incumbents with more resources may develop superior or faster-to-market solutions. |
| Business quality | Medium | The reliance on a single lead candidate and unproven delivery platform creates significant concentration risk. |
| Dividend income | Low / none | The company is not an income-generating entity. |
| Execution risk | High | Regulatory hurdles and clinical trial design are significant barriers that could halt the company's progress. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -86.34% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/24/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 28.44M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 83.7K shares | Beta 1.17 | 52 Weeks Range 1.58 - 20.99 | Updated Date 09/24/2026 |
52 Weeks Range 1.58 - 20.99 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -45.83 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Stage Research | Potential future licensing, milestone payments, or drug commercialization. | The company currently makes no money and relies on capital raises to fund research. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 188.29M | Price to Sales(TTM) - |
Enterprise Value 188.29M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.59 | Shares Outstanding 16.93M | Shares Floating 2.15M |
Shares Outstanding 16.93M | Shares Floating 2.15M | ||
Percent Insiders 1.78 | Percent Institutions 0.44 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Transcode Therapeutics Inc
Exchange NASDAQ | Headquarters Boston, MA, United States | ||
IPO Launch date 2021-07-08 | CEO & Executive Chairman of the Board Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | |
Full time employees 12 | |||
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor. The company is also developing oncolytic virus therapy. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.